Cargando…

The mutation profiles of cell-free DNA in patients with oesophageal squamous cell carcinoma who were responsive and non-responsive to neoadjuvant chemotherapy

BACKGROUND: The aim of this study was to evaluate the clinical value of plasma cell-free DNA (cfDNA) mutation profiles in patients with oesophageal squamous cell carcinoma (OSCC) who received neoadjuvant chemotherapy. METHODS: Twenty-two OSCC patients received neoadjuvant chemotherapy and were divid...

Descripción completa

Detalles Bibliográficos
Autores principales:	Zhang, Ruixiang, Hu, Ying, Zhou, Tao, Han, Wenbo, Liu, Yang, Qian, Juanjuan, Chen, Yanhui, Liu, Xianben, Liu, Shilei, Yu, Yongkui, Zeng, Hui, Zhang, Henghui, Li, Yin
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	AME Publishing Company 2020
Materias:	Original Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7475527/ https://www.ncbi.nlm.nih.gov/pubmed/32944339 http://dx.doi.org/10.21037/jtd-20-230

Ejemplares similares

The Role of Adjuvant Chemotherapy in the Treatment of Esophageal Squamous Cell Carcinoma after Neoadjuvant Chemotherapy
por: Li, Keting, et al.
Publicado: (2023)

Reevaluation of Neoadjuvant Chemotherapy for Esophageal Squamous Cell Carcinoma: A Meta-Analysis of Randomized Controlled Trials Over the Past 20 Years
por: Zheng, Yan, et al.
Publicado: (2015)

Neoadjuvant chemotherapy followed by minimally invasive esophagectomy versus primary surgery for management of esophageal carcinoma: a retrospective study
por: Zheng, Yan, et al.
Publicado: (2019)

Neoadjuvant Chemotherapy Compared with Surgery for Oesophageal Carcinoma: A Retrospective Study and Missing Evidence
por: Zheng, Yan, et al.
Publicado: (2023)

Clinical Response to Neoadjuvant Immunotherapy Combined with Targeted Therapy and Chemotherapy in Oral Squamous Cell Carcinoma: Experience in Three Patients
por: Tian, Yu, et al.
Publicado: (2022)

Right Compared With Left Thoracic Approach Esophagectomy for Patients With Middle Esophageal Squamous Cell Carcinoma
por: Zheng, Yan, et al.
Publicado: (2020)

Pathological response to neoadjuvant chemoradiotherapy for oesophageal squamous cell carcinoma: multicentre East Asian and Dutch database comparison
por: Eyck, Ben M, et al.
Publicado: (2022)

The safety of neoadjuvant chemotherapy combined with non-tube nofasting fast-track surgery for esophageal carcinoma
por: Zheng, Yan, et al.
Publicado: (2022)

Analysis of the associated factors for severe weight loss after minimally invasive McKeown esophagectomy
por: Wang, Peiyu, et al.
Publicado: (2018)

Prognostic implications of the extent of downstaging after neoadjuvant therapy for oesophageal adenocarcinoma and oesophageal squamous cell carcinoma
por: Kamarajah, Sivesh K, et al.
Publicado: (2023)

Predicting Response to Neoadjuvant Therapy in Oesophageal Adenocarcinoma
por: Jiang, William, et al.
Publicado: (2022)

Neoadjuvant chemotherapy versus neoadjuvant chemoradiotherapy for locally advanced oesophageal squamous cell carcinoma: a single-Centre, open-label, randomized, controlled, clinical trial (HCHTOG1903)
por: Sun, Hai-Bo, et al.
Publicado: (2020)

Neoadjuvant camrelizumab plus chemotherapy in locally advanced oesophageal squamous cell carcinoma: a retrospective cohort study
por: Zhou, Rui-Qin, et al.
Publicado: (2023)

Neoadjuvant therapy combined with surgery is superior to chemoradiotherapy in esophageal squamous cell cancer patients with resectable supraclavicular lymph node metastasis: a propensity score-matched analysis
por: Yu, Yongkui, et al.
Publicado: (2022)

Association between alcohol consumption and oesophageal microbiota in oesophageal squamous cell carcinoma
por: Rao, Wenqing, et al.
Publicado: (2021)

Neutrophil to lymphocyte ratio as a predictor of response to neoadjuvant chemotherapy and survival in oesophageal adenocarcinoma
por: Powell, A. G. M. T., et al.
Publicado: (2020)

Transcriptomic biomarkers for predicting response to neoadjuvant treatment in oesophageal cancer
por: Lavery, Anita, et al.
Publicado: (2021)

Clinical value of hematologic test in predicting tumor response to neoadjuvant chemotherapy with esophageal squamous cell carcinoma
por: Liu, Yinan, et al.
Publicado: (2014)

The predictive value of peripheral blood cells and lymphocyte subsets in oesophageal squamous cell cancer patients with neoadjuvant chemoradiotherapy
por: Zhou, Jin, et al.
Publicado: (2022)

Update on Neoadjuvant Regimens for Patients with Operable Oesophageal/Gastrooesophageal Junction Adenocarcinomas and Squamous Cell Carcinomas
por: Cox, Samantha J., et al.
Publicado: (2017)

Post-neoadjuvant cellular dissociation grading based on tumour budding and cell nest size is associated with therapy response and survival in oesophageal squamous cell carcinoma
por: Jesinghaus, Moritz, et al.
Publicado: (2019)

Lactate Dehydrogenase B Is Associated with the Response to Neoadjuvant Chemotherapy in Oral Squamous Cell Carcinoma
por: Sun, Wenyi, et al.
Publicado: (2015)

Author response to: Neoadjuvant chemoradiotherapy or chemotherapy alone for oesophageal cancer: population-based cohort study
por: Kamarajah, S K, et al.
Publicado: (2021)

Serum Fibrinogen Is An Independent Prognostic Factor In Operable Esophageal Squamous Carcinoma: A Real-World Study
por: Zheng, Yan, et al.
Publicado: (2019)

PD-L1 expression and tumor mutational burden status for prediction of response to chemotherapy and targeted therapy in non-small cell lung cancer
por: Chen, Yanhui, et al.
Publicado: (2019)

Diagnostic performance of MRI for assessment of response to neoadjuvant chemoradiotherapy in oesophageal cancer
por: Vollenbrock, S. E., et al.
Publicado: (2019)

The Use of miRNAs in Predicting Response to Neoadjuvant Therapy in Oesophageal Cancer
por: Lang, Cameron C. J., et al.
Publicado: (2022)

The Sequence of Chemotherapy and Toripalimab Might Influence the Efficacy of Neoadjuvant Chemoimmunotherapy in Locally Advanced Esophageal Squamous Cell Cancer—A Phase II Study
por: Xing, Wenqun, et al.
Publicado: (2021)

Oral Microbiome in Patients with Oesophageal Squamous Cell Carcinoma
por: Wang, Qian, et al.
Publicado: (2019)

Multicentre Comparison of the Toxicity and Effectiveness of Lobaplatin-Based Versus Cisplatin-Based Adjuvant Chemotherapy in Oesophageal Carcinoma
por: Zheng, Yan, et al.
Publicado: (2021)

RPN2 expression predicts response to docetaxel in oesophageal squamous cell carcinoma
por: Kurashige, J, et al.
Publicado: (2012)

Neoadjuvant versus definitive radiochemotherapy of locoregionally advanced oesophageal cancer—who benefits?
por: Schiffner, Christoph, et al.
Publicado: (2022)

Pembrolizumab Combined With Neoadjuvant Chemotherapy Versus Neoadjuvant Chemoradiotherapy Followed by Surgery for Locally Advanced Oesophageal Squamous Cell Carcinoma: Protocol for a Multicentre, Prospective, Randomized-Controlled, Phase III Clinical Study (Keystone-002)
por: Shang, Xiaobin, et al.
Publicado: (2022)

Active surveillance of oesophageal cancer after response to neoadjuvant chemoradiotherapy: dysphagia is uncommon
por: Valkema, Maria J, et al.
Publicado: (2023)

Tailoring neoadjuvant chemotherapy for patients with breast cancer who have achieved pathologic complete response
por: Li, Xianjun, et al.
Publicado: (2020)

Controversies in upper gastrointestinal oncology: neoadjuvant chemoradiotherapy versus neoadjuvant chemotherapy in oesophageal adenocarcinoma
por: Petrillo, A., et al.
Publicado: (2022)

Silencing of methyltransferase-like 3 inhibits oesophageal squamous cell carcinoma
por: Hu, Wen, et al.
Publicado: (2020)

Expression of angiogenic factors predicts response to chemoradiotherapy and prognosis of oesophageal squamous cell carcinoma
por: Shimada, H, et al.
Publicado: (2002)

Prognostic significance of PET assessment of metabolic response to therapy in oesophageal squamous cell carcinoma
por: Chhabra, Arpit, et al.
Publicado: (2015)

MMS22L Expression as a Predictive Biomarker for the Efficacy of Neoadjuvant Chemoradiotherapy in Oesophageal Squamous Cell Carcinoma
por: Luo, Qiyu, et al.
Publicado: (2021)

Cannot write session to /tmp/vufind_sessions/sess_hrikc2b5heafsl4hejfvtjse8a